Seth Ettenberg, PhD, is the current President and CEO of BlueRock Therapeutics. Seth served as Chief Scientific Officer at BlueRock from 2020 – 2021. Prior to joining BlueRock, Seth was a founding member of the Unum Therapeutics team, where he served as Chief Scientific Officer. Previously, Seth headed the Cambridge Site of Novartis’ Oncology Biotherapeutics, leading strategy, innovation, and implementation of drug development projects of Novartis Institutes for Biomedical Research (NIBR). In addition, Seth was responsible for building and leading the Novartis Cell and Gene Therapy research team in collaboration with the University of Pennsylvania to develop chimeric antigen receptor T-cell therapeutics. Seth received his formal scientific training at the Genetics Branch of the National Cancer Institute.
Seth Ettenberg, PhD
President & CEO, BlueRock Therapeutics